Melanoma Coverage from Every Angle

MEK Inhibitor Under Study for Treatment of Brain Metastases From Melanoma

By: Andrew Goldstein
Posted: Monday, February 4, 2019

Hani Babiker, MD, of the University of Arizona Cancer Center, and colleagues have opened a clinical trial for patients with brain metastases from BRAF- or MEK-mutated melanoma ( identifier NCT03332589). The patients will be treated with an investigational MEK inhibitor called E6201, which appears to be effective at crossing the blood-brain barrier.

E6201 was already tested in a phase I trial involving 55 patients with various tumor types, including 22 patients with BRAF-mutated melanoma. A total of 9 patients had brain metastases, and 2 of them achieved clinical responses lasting more than 4 years; 1 of these patients continued taking the drug for more than 8 years with a continued near-complete response.

“We’re going to look at safety, tumor regression, survival, and progression-free survival,” commented Dr. Babiker in an institutional press release. “The next step might be comparing it to another drug or combining it with another drug in a larger study.” 

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.